Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProstACT Global Japan: 177Lu-TLX591 + SOC vs SOC in PSMA-positive mCRPC
jRCT2031250333Phase 3Not yet recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing 177Lu-TLX591 + Standard of Care with Standard of Care Alone (2 arms). Primary endpoints: Clinical safety and tolerability of 177Lu-TLX591, Pharmacokinetics of 177Lu-TLX591 and 6 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
177lu-rosopatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250333.